Search results
Results from the WOW.Com Content Network
A 2007 review by Leonard Calabrese and colleagues proposed the name reversible cerebral vasoconstriction syndrome, which has since gained widespread acceptance. [1] [9] This name merges various conditions that were previously treated as distinct entities, including Call-Fleming syndrome, postpartum angiopathy, and drug-induced angiopathy. [6]
In March 2020, then US President Donald Trump promoted the use of chloroquine and hydroxychloroquine, two related anti-malarial drugs, for treating COVID-19. The FDA later clarified that it has not approved any therapeutics or drugs to treat COVID-19, but that studies were underway to see if chloroquine could be effective in treatment of COVID-19.
An old and commonly prescribed diabetes medication may help significantly lower the risk of developing long COVID, recently released drug trial data show.. The trial, conducted by a team of ...
Antiviral medications were tried in people with severe disease. [1] As of March 2020 several medications were already approved for other uses or were already in advanced testing. [43] As of April 2020 trials were investigating whether existing medications could be used effectively against the body's immune reaction to SARS-CoV-2 infection.
(Reuters) -The U.S. Food and Drug Administration on Friday warned patients and doctors about dosing errors associated with compounded versions of Novo Nordisk's weight-loss and diabetes drugs.
The time to peak concentrations of nirmatrelvir combined with ritonavir is 3.00 hours (range 1.02–6.00 hours), while that of ritonavir is 3.98 hours. [10] Peak concentrations of nirmatrelvir combined with ritonavir following a single dose (300 mg nirmatrelvir and 100 mg ritonavir) in healthy individuals are 2.21 μg/mL while total exposure is ...
Both treatments are for individuals that have mild to moderate COVID-19 symptoms in the last five days and are at a higher risk of getting more serious reactions.
On 21 November 2020, the U.S. Food and Drug Administration (FDA) issued an emergency use authorization (EUA) for casirivimab and imdevimab to be administered together for the treatment of mild to moderate [COVID‑19] in people twelve years of age or older weighing at least 40 kilograms (88 lb) with positive results of direct SARS-CoV-2 viral ...